TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03760484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg
Description: Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation (FMT)
Description: Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
Study: NCT05302323

Intervention type: OTHER
Group type: OTHER
Intervention: Disposable Drape
Description: Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300mg NANO-Efavirenz
Description: OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 600mg Sustiva
Description: OD
Study: NCT05302323

Intervention type: OTHER
Group type: OTHER
Intervention: Reusable Drape
Description: Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
Study: NCT00332956

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rFIV vaccine
Description: rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine 160 mcg given on Study Days 0, 56, 182
Description: rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
Study: NCT00721487

Intervention type: DRUG
Intervention: Fluconazole
Description: Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
Study: NCT03926676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: grandio blocks
Description: nano hybrid composite blocks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grandio blocks
Description: nano hybrid composite blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emax
Description: ceramic blocks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emax
Description: ceramic blocks
Study: NCT01062360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine
Description: Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study: NCT02168686

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg NANO-Efavirenz
Description: OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kaletra® (lopinavir 400mg/ritonavir 100mg)
Description: BID
Study: NCT02168686

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-043
Description: Gene transfer vector administration
Study: NCT03394560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High frequency repetitive transcranial magnetic stimulation
Description: Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
Study: NCT04214847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve surgery
Description: The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve surgery
Description: The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
Study: NCT03233932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LeuplinⓡInj
Description: Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-841
Description: Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
Study: NCT02245048

Intervention type: OTHER
Intervention: Carotid Intima-Media Thickness (CIMT)
Study: NCT00578123

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
Study: NCT02862314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT05145621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod 0.5 mg capsules- Test drug
Description: An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod 0.5 mg capsules- Test drug
Description: An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
Study: NCT04390867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS1 DBS
Description: TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kaletra® (lopinavir 400mg/ritonavir 100mg)
Description: BID
Study: NCT04390867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS2 DBS
Description: TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS3 DBS
Description: TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg NANO-Lopinavir
Description: BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg NANO-Lopinavir
Description: BID
Study: NCT04390867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard DBS
Description: Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
Study: NCT03592979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study: NCT03120169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill endurance training
Description: n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cycling endurance training
Description: n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
Study: NCT02977923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR distraction via Oculus Rift
Description: In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pharmacological treatment
Description: according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
Study: NCT03414957

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal and biochemical blood tests and ultrasound scanning
Description: Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal and biochemical blood tests and ultrasound scanning
Description: Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
Study: NCT04505683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benapenem
Description: Benapenem for IV injection administered as a 1-gram IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem for IV injection administered as a 1-gram IV infusion
Study: NCT03777449

Intervention type: RADIATION
Intervention: CBCT
Description: Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.

Intervention type: RADIATION
Intervention: CBCT
Description: Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
Study: NCT02656927

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Condition
Study: NCT01515527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
Study: NCT02077933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
Study: NCT03857789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A 40 question frailty questionnaire.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: A 40 question frailty questionnaire.
Study: NCT02460211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
Study: NCT02631473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg ritonavir NORVIR
Description: BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg ritonavir NORVIR
Description: BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg Sustiva
Study: NCT00536211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral tablet, 1000 mg daily for 17 days
Study: NCT01815541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teicoplanin
Study: NCT03445156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game
Description: Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game
Description: Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
Study: NCT02045381

Intervention type: PROCEDURE
Intervention: MRI Group
Description: A single research MRI
Study: NCT03445156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controller
Description: Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.